All In Biotech

Drug Trial Radar · NCT06189963

Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Nov 21, 2023

Primary completion

Mar 2028

Study completion Jun 2028

Sponsor

Lead sponsor
NKGen Biotech, Inc.Industry
Sponsor type
Industry
First posted
Jan 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion 2. Can SNK01 administration improve cognitive assessment scores and biomarkers

Conditions

  • Moderate Alzheimer Disease

Interventions

  • SNK01Biological

    SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug

  • PlaceboOther

    Sodium Lactate Hartmann's Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose-limiting toxicityTime frame: 3 weeks
  2. Maximum tolerated dose determinationTime frame: 3 weeks
  3. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0Time frame: 1 Year
  4. Preliminary efficacy in cognitive assessment scores of CDR-SBTime frame: 1 Year
  5. Preliminary efficacy in cognitive assessment scores of MMSETime frame: 1 Year
  6. Preliminary efficacy in cognitive assessment scores of NPITime frame: 1 Year
  7. Preliminary efficacy in cognitive assessment scores of ADCS-ADL-SevereTime frame: 1 Year
  8. Preliminary efficacy in cognitive assessment scores of ADAS-CogTime frame: 1 Year

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Behavioral Research Specialists, LLC

    Glendale, California · Recruiting

  • Syrentis Clinical Research

    Santa Ana, California · Recruiting

  • Valiance Clinical Research

    Tarzana, California · Withdrawn

  • K2 Medical Research

    Maitland, Florida · Recruiting

  • AdventHealth Research Institute

    Orlando, Florida · Recruiting

  • Rutgers Health

    Newark, New Jersey · Recruiting

  • Alzheimer's Disease Research Center

    Albany, New York · Recruiting

  • Ottawa Memory Clinic

    Ottawa, Ontario, Canada · Withdrawn

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.